Epidermal Growth Factor Tyrosine Kinase Inhibitor Therapy Inferior to Second-Line Chemotherapy in EGFR Wild-Type Non-Small Cell Lung Cancer Patients: Results of French Nationwide Observational Study
Translational Lung Cancer Research - Hong Kong
doi 10.21037/tlcr.2017.10.16
Full Text
Open PDFAbstract
Available in full text
Categories
Date
December 1, 2017
Authors
Publisher
AME Publishing Company